Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$4.05
+3.1%		$3.97
$3.41
▼
$5.36
$158.67M1.082,797 shs350 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-3.85%+3.08%+3.08%-4.46%+7.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$4.05
+3.1%		$3.97
$3.41
▼
$5.36
$158.67M1.082,797 shs350 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-3.85%+3.08%+3.08%-4.46%+7.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
2.25
Hold$8.38106.74% Upside

Current Analyst Ratings Breakdown

Latest MOLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2026
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/6/2026
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$5.65M28.95N/AN/A$2.40 per share1.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$74.41M-$1.94N/AN/AN/AN/A-66.62%-54.85%8/25/2026 (Estimated)

Latest MOLN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/25/2026Q2 2026
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$0.45N/AN/AN/AN/AN/A
5/11/2026Q1 2026
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$0.4340-$0.45-$0.0160-$0.44N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/A
9.43
9.43

Institutional Ownership

CompanyInstitutional Ownership
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
26.55%

Insider Ownership

CompanyInsider Ownership
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
5.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
18040.38 million37.98 millionNot Optionable

Recent News About These Companies

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327452/0/en/molecular-partners-showcases-bispecific-radio-darpins-at-gordon-research-conference.html
LifeSci Capital Sticks to Their Buy Rating for Molecular Partners (MOLN)
July 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3244163/lifesci-capital-sticks-to-their-buy-rating-for-molecular-partners-moln/
Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Declines By 84.3%
July 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-molecular-partners-ag-sponsored-adr-nasdaqmoln-declines-by-843-2026-07-11/
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
July 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/06/3322137/0/en/molecular-partners-updates-on-clinical-progress-across-expanding-pipeline-of-darpin-radiotherapeutics.html
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321081/0/en/molecular-partners-and-orano-med-announce-first-patients-dosed-in-phase-1-2a-trial-of-dll3-radio-darpin-mp0712.html
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
May 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/30/3303874/0/en/molecular-partners-holds-presentations-at-asco-and-snmmi-2026-on-dll3-targeting-radio-darpin-mp0712-now-dosing-patients-in-phase-1.html
Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301431/0/en/molecular-partners-to-present-at-td-cowen-s-7th-annual-oncology-innovation-summit.html
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3293343/0/en/molecular-partners-reports-financial-results-and-highlights-for-q1-2026-with-clinical-studies-initiated-on-mp0712-and-mp0317.html
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
May 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3286406/0/en/molecular-partners-to-hold-oral-presentations-on-dll3-targeting-radio-darpin-candidate-mp0712-at-multiple-upcoming-scientific-conferences.html
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
May 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/01/3285827/0/en/molecular-partners-publishes-phase-1-mp0317-data-in-nature-cancer-demonstrating-tumor-localized-cd40-activation-and-tumor-microenvironment-remodeling.html
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
April 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/19/3276658/0/en/molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-switch-darpin-t-cell-engager-mp0632-and-dll3-radio-darpin-mp0712.html
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
April 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/14/3273886/0/en/molecular-partners-announces-all-board-proposals-approved-clare-fisher-elected-as-new-board-member-at-annual-general-meeting.html
Molecular Partners AG Sponsored ADR
April 10, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/MOLN
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
March 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/23/3260418/0/en/molecular-partners-publishes-invitation-to-annual-general-meeting-2026-and-proposes-clare-fisher-for-election-to-its-board-of-directors.html
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes
March 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/19/3258733/0/en/molecular-partners-presents-new-preclinical-data-highlighting-radio-darpins-amenability-to-multiple-isotopes.html
Molecular Partners to Hold Three Poster Presentations at AACR 2026
March 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/17/3257681/0/en/molecular-partners-to-hold-three-poster-presentations-at-aacr-2026.html
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
March 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/12/3255073/0/en/molecular-partners-reports-highlights-and-financial-results-for-full-year-2025.html
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
February 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/molecular-partners-signs-development-agreement-060000893.html
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
February 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/26/3245189/0/en/molecular-partners-announces-participation-in-march-investor-conferences-and-upcoming-2025-financial-results.html
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
February 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4864945-molecular-partners-ag-moln-discusses-clinical-imaging-and-dosimetry-data-for-dll3-targeting
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
February 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/02/3229944/0/en/molecular-partners-announces-presentation-of-first-imaging-and-dosimetry-data-of-dll3-targeting-radiotherapy-mp0712-in-patients-at-twc-2026.html

Media Sentiment Over Time

Molecular Partners stock logo

Molecular Partners NASDAQ:MOLN

$4.05 +0.12 (+3.08%)
Closing price 07/31/2026 03:54 PM Eastern
Extended Trading
$4.08 +0.03 (+0.69%)
As of 07/31/2026 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas